RVX-208, also known as RVX000222, is primarily investigated for its potential therapeutic applications in cardiovascular diseases. It functions as a bromodomain and extra-terminal (BET) inhibitor, specifically targeting the BET protein BRD4. This mechanism is believed to enhance the expression of apolipoprotein A-I (ApoA-I), a key component of high-density lipoprotein (HDL) or "good cholesterol." By increasing ApoA-I levels, RVX-208 promotes the formation of HDL particles, which play a critical role in reverse cholesterol transport—a process that helps remove excess cholesterol from arteries and reduces the risk of atherosclerosis. Clinical studies have explored its use in treating conditions like acute coronary syndrome and other cardiovascular disorders, aiming to improve lipid profiles and reduce cardiovascular events. Additionally, its potential anti-inflammatory properties are being studied for broader applications in chronic inflammatory diseases.